Press Release: Sanofi initiates phase 3 program for PCV21 - GlobeNewswire
Sanofi and SK bioscience expand collaboration to develop next-gen pneumococcal conjugate vaccines (PCVs), initiating phase 3 for PCV21, the first 21-valent PCV candidate in infants & toddlers. The partnership aims to address unmet needs in invasive pneumococcal disease, leveraging both companies' expertise and capabilities.
Highlighted Terms
Related News
Press Release: Sanofi initiates phase 3 program for PCV21 - GlobeNewswire
Sanofi and SK bioscience expand collaboration to develop next-gen pneumococcal conjugate vaccines (PCVs), initiating phase 3 for PCV21, the first 21-valent PCV candidate in infants & toddlers. The partnership aims to address unmet needs in invasive pneumococcal disease, leveraging both companies' expertise and capabilities.